Analyzing genomic traits of lung cancers found through screening
Analysis of Screen-detected Lung Cancers' Genomic Traits
This study looks at the genetic features of lung cancers found through screening to see how they relate to other tests and help improve the safety and understanding of these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 526 (estimated) |
| Ages | 50 Years to 77 Years |
| Sex | All |
| Sponsor | University College, London Academic / other |
| Locations | 2 sites (London and 1 other locations) |
| Trial ID | NCT04204499 on ClinicalTrials.gov |
What this trial studies
This observational cohort study focuses on patients who have been diagnosed with lung cancer through low dose CT screening. It aims to investigate the genomic signatures of these screen-detected cancers and correlate them with non-invasive biological and radiological parameters. By understanding the biological behavior of these lesions, the study seeks to develop strategies for characterizing lung cancers detected by screening, potentially reducing the risks associated with screening procedures.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with lung cancer or probable lung cancer via LDCT screening who are scheduled for or have undergone surgical resection.
Not a fit: Patients who have received neoadjuvant therapy for lung cancer or have active viral infections such as HIV or Hepatitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for identifying and managing lung cancers detected through screening, enhancing patient outcomes.
How similar studies have performed: Other studies have explored genomic traits in lung cancer, but this specific approach focusing on screen-detected cancers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening. 2. Planned for, or completed primary surgical resection either for histologically confirmed lung cancer, or strongly suspected lung cancer. 3. Able to provide written informed consent (or verbal informed consent for participants consenting to retrospective diagnostic samples and data collection only). Exclusion Criteria: 1. Treatment with neoadjuvant therapy for current lung malignancy as per local MDT treatment decision. 2. Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus or Syphilis.
Where this trial is running
London and 1 other locations
- St Bart's Hospital — London, United Kingdom (Recruiting)
- Uclh — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Sam Janes — Ucl
- Study coordinator: Laura Hughes
- Email: ctc.ascent@ucl.ac.uk
- Phone: 0207 679 9284
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.